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Ivabradine is a novel heart rate lowering agent that inhibits If ionic current in the sinus node and demonstrates antiischaemic and
antianginal activity. The aim of the paper was to investigate the eﬀect its dose-dependent drug-drug interaction with simvastatin
inhibitor HMGCo-A has on PAI-1 blood level, heart rate and blood pressure. The experiments were performed in hyper- and
normocholesterolemic Wistar rats receiving simvastatin (1 and 20mg × kg
−1 bw) with ivabradine (10mg × kg
−1 bw) during a
4-week period. Ivabradine exacerbated the decrease of PAI-1 in normocholesterolemic animals receiving simvastatin at a dose
of 1 mg/kg bw and was not observed to have any signiﬁcant inﬂuence on the PAI-1 values in rats receiving 20mg × kg
−1 bw
simvastatin. Ivabradine, coadministered with simvastatin given at a dose of 20mg × kg
−1 bw, signiﬁcantly slowed the heart rate
in normocholesterolaemic and hypercholesterolaemic groups as compared to the group receiving ivabradine alone. Conclusion.
The administration of ivabradine to normocholesterolaemic and hypercholesterolaemic rats receiving simvastatin signiﬁcantly
exacerbated the slowing of heart rate with no eﬀect on blood pressure. The administration of ivabradine has been shown to
demonstrate diﬀerent eﬀects on PAI-1 values depending on lipid disorders.
1.Introduction
The resting heart rate value acts as an independent factor
of the risk associated with cardiovascular problems [1–3].
A signiﬁcant advantage of the slowing of the heart rate is
connected with reduced demand of the heart muscles for
oxygen, as well as a beneﬁcial inﬂuence on the function
of the blood vessel endothelium [4, 5]. The novel selective
for the If current lowering heart rate agent, speciﬁcally
slow cardiac frequency, by decreasing the rate of diastolic
depolarization [6]. Ivabradine seems to have an additional
eﬀect in patients with stabile coronary artery disease (CAD)
withoutandwithleftventricularsystolicdysfunction(LVSD)
[7–9]. Preclinical studies show that inhibition of the HCN
channel slows the rhythm to varying degrees in the atria,
ventricle, and outﬂow tract [10]. Ivabradine reduces heart
rate in the sinoatrial node without aﬀecting blood pressure
or myocardial contractility, intracardiac conduction, or
ventricular repolarization [11]. In ischaemic heart disease
(IHD) patients, the role played by HMGCo-A inhibitors in
the prevention of cardiovascular events is well established.
Their beneﬁcial activity is dependent on the limitation
of cholesterol synthesis as well as cholesterol-independent
“pleiotropic”eﬀects[12].Ithasbeenshowninearlierclinical
studies that simvastatin at a dose of 40mg/day given for
a period of 8 weeks signiﬁcantly reduced the levels of
inﬂammatory markers [13] as well as inhibited the activity
of the circulating ﬁbrinolysis inhibitor factor-plasminogen
activator inhibitor 1(PAI-1) [14]. Similar observations have
been noted in laboratory studies [15]. The inﬂuence on
ﬁbrinolysis processes were then observed depending on the
“mechanism that involves geranylgeranyl-modiﬁed interme-
diates.”
The aim of this paper was to assess the impact of the
administration of ivabradine alone and combined with2 The Scientiﬁc World Journal
various doses of simvastatin on PAI-1 and heart rate
values in normocholesterolaemic and hypercholesterolaemic
rats.
2.MaterialsandMethods
2.1. Study Protocol. The study was approved by the Ethics
Committee of the Medical University of Lodz (Poland)–
2/ŁB441/2009.Theexperimentswereperformedin101,Wis-
tar rats, outbred males, 200–240gbw. An adaptation period
lasting several days was scheduled prior to the beginning
of the experiment. After the adaptation period, animals
were divided into 2 groups: those receiving a normal diet
(normocholesterolaemic rats) or those receiving a diet with
5% cholesterol and 2.5% cholic acid (hypercholesterolaemic
rats). After a four-week period, each group was divided into
6 subgroups which, for 4 weeks, received intragastric (i.g.)
doses of:
(1) 0.1% methylcellulose (control group);
(2) ivabradine 10mg × kg−1 bw;
(3) simvastatin 1mg × kg−1 bw;
(4) simvastatin 20mg × kg−1 bw;
(5) simvastatin 1mg × kg−1 bw + Ivabradine 10mg ×
kg−1 bw;
(6) simvastatin 20mg × kg−1 bw + Ivabradine 10mg ×
kg−1 bw.
All rats had free access to food and water throughout
the study. After an eight-week period of diet and drug
administration, heart rate, and hemodynamic parameters
weremeasured.Thesurgerywasperformed24hafteradmin-
istration of the last drug dose and 10h after the last feed
supply. For the further surgical procedures, anesthesia was
initiated by an intraperitoneal (i.p.) dose of pentobarbital
sodium at 60mg × kg−1 bw. The anesthesia was maintained
by intraperitoneal bolus injections of pentobarbital sodium
at10mg ×kg−1 bwasneeded.Forthemeasurementsofheart
rate, and blood pressure, catheters were implanted into the
right carotid artery. The signals were provided by an Isotec
pressure transducer connected to a direct current bridge
ampliﬁer (both Hugo Sachs Elektronik) for 20 minutes
after the hemodynamic parameter stabilization period. For
the further PAI-1 assessment and lipid proﬁle examination,
blood samples were taken. Surgical procedures, heart rate
and blood pressure recording were provided as described
previously [16, 17]. Plasma PAI-1 levels were determined
using ELISA kits from American Diagnostica following the
manufacturer’s instructions.
2.2. Statistics. All data were presented as means ± SD (stan-
dard deviation). Statistical comparisons between the groups
were performed using ANOVA, and post hoc comparisons
were performed using the LSD test. The normal distribution
of parameters was checked by means of the Shapiro-Wilks
test. If the data was not normally distributed or the values
of variance were diﬀerent, ANOVA with Kruscal-Wallis and
Mann-Whitney’s U test were used. All parameters were
considered signiﬁcantly diﬀerent if P<0.05. The statistical
analysis of heart rate and hemodynamic parameters was
performed using Statgraphics 5.0 plus software.
3. Results
3.1. Lipid Proﬁle. The lipid proﬁles achieved in normo-
cholesterolaemic and hypercholesterolaemic rats are pre-
sented in Tables 1 and 2.
3.2. Blood Pressure. Ivabradine and simvastatin given alone
or in combination was found to have an insigniﬁcant
inﬂuence on the mean, systolic, and diastolic blood pressure
in normocholesterolaemic and hypercholesterolaemic rats
(Tables 3 and 4).
3.3.HeartRate. Innormocholesterolaemicandhypercholes-
terolaemic rats receiving simvastatin at doses of 1 and
20mg × kg−1 bw alone, no signiﬁcant diﬀerences were seen
in the heart rate disturbances compared to control groups.
Ivabradine administration to normocholesterolaemic rats
resulted in signiﬁcant deceleration of heart rate compared to
the control group (350.2 ± 16.2 versus 434.8 ± 17.2min−1).
Similar results were also observed in the hypercholestero-
laemic group (363 ± 21.7 versus 435.3 ± 20.3min−1).
The heart rate values after concomitant administration of
ivabradine and simvastatin at a dose of 1mg × kg−1 bw
to normocholesterolaemic rats were signiﬁcantly decreased
compared to the control group (342.3 ± 28.6 versus 434.8 ±
17.2min−1)andcomparedtothegroupreceivingsimvastatin
alone. Similar observations were made in hypercholestero-
laemic rats. There were no statistical diﬀerences in heart
rate concerning concomitant administration of ivabradine
and simvastatin at dose 1mg × kg−1 bw between hyper- and
normocholesterolaemic rats. Administration of ivabradine
withsimvastatinatadoseof20mg×kg
−1 bwtohypercholes-
terolaemic rats signiﬁcantly reduced heart rate compared to
the control group (319.6 ± 30.6 versus 435.3 ± 20.3min−1)
and compared to the groups receiving simvastatin at a dose
o f1o r2 0m g×kg
−1 bw alone.
In the normocholesterolaemic group, the slowing of the
heart rate was statistically similar to hypercholesterolaemic
rats. Administration of ivabradine with simvastatin at a
dose of 20mg × kg
−1 bw to hypercholesterolaemic and nor-
mocholesterolaemic rats similarly decreased heart rate. The
concomitant administration of ivabradine with simvastatin
at a dose of 20mg × kg
−1 bw to hypercholesterolaemic and
normocholesterolaemic was shown to signiﬁcantly decrease
the heart rate compared to rats receiving ivabradine alone
(Figures 3 and 4).
3.4. PAI-1 Blood Level. In normocholesterolaemic rats, the
administration of ivabradine was seen to have no statistically
signiﬁcantinﬂuenceonPAI-1valuescomparedtothecontrol
group or the group receiving 1mg/kgbw of simvastatin
alone. The administration of simvastatin at dose of 20mg/kg
signiﬁcantly (P<0.05) reduced the levels of PAI-1 compared
to the control group. After a combined dose of ivabradineThe Scientiﬁc World Journal 3
Table 1: Total cholesterol (TCH), HDL-cholesterol, LDL-cholesterol, and triglycerides (TGs) (mean ± SD) in rats fed normocholestero-
laemic diet (mmol/l).
TCH HDL LDL TGs
K N( n = 10) 1,48 ± 0,12 0,38 ± 0,09 0,95 ± 0,29 0,32 ± 0,13
IW N( n = 9) 1,11 ± 0,03 0,34 ± 0,08 0,65 ± 0,17 0,25 ± 0,08
S1 N( n = 10) 1,34 ± 0,21 0,57 ± 0,05∗ 0,56 ± 0,14∗ 0,46 ± 0,14
S20 N( n = 7) 1,39 ± 0,14 0,69 ± 0,14∗ 0,44 ± 0,09∗ 0,56 ± 0,18
IW N S1 (n = 6) 1,53 ± 0,14 0,64 ± 0,15∗ 0,61 ± 0,09∗ 0,62 ± 0,26
IW N S20 (n = 8) 1,37 ± 0,12 0,56 ± 0,18∗ 0,59 ± 0,10∗ 0,48 ± 0,15
K N: normocholesterolaemic control group, IW N: normocholesterolaemic group receiving ivabradine, S1 N: normocholesterolaemic group receiving
simvastatin at a dose of 1mg × kg−1bw, S20 N: normocholesterolaemic group receiving simvastatin at a dose of 20mg × kg−1bw, IW N S1: normoc-
holesterolaemic group receiving ivabradine and simvastatin at a dose of 1mg × kg−1bw, IW N S20: normocholesterolaemic group receiving ivabradine and
simvastatin at a dose of 20mg × kg−1bw ∗P<0.05 as compared to the control group.
Table 2:Totalcholesterol(TCH),HDL-cholesterol,LDL-cholesterol,andtriglycerides(TGs)(mean ±SD)inratsfedhypercholesterolaemic
diet (mmol/l).
TCH HDL LDL TGs
K H( n = 10) 8,09 ± 1,53 0,36 ± 0,09 6,25 ± 0,65 3,24 ± 0,67
IW H( n = 9) 7,53 ± 1,17 0,38 ± 0,11 5,98 ± 0,82 2,57 ± 0,11
S1 H( n = 8) 6,35 ± 1,81 0,61 ± 0,12∗ 4,45 ± 0,21∗ 2,82 ± 0,57
S20 H( n = 9) 2,01 ± 0,16∗ 0,42 ± 0,14∗ 1,29 ± 0,92∗ 0,65 ± 0,64∗
IW H S1 (n = 8) 7,25 ± 0,67 0,69 ± 0,04∗ 4,94 ± 0,33∗ 3,50 ± 0,82
IW H S20 (n = 7) 1,34 ± 0,15∗ 0,33 ± 0,04∗ 0,16 ± 0,03∗ 0,96 ± 0,23∗
K H: hypercholesterolaemic control group, IW H: hypercholesterolaemic group receiving ivabradine, S1 H: hypercholesterolaemic group receiving simvas-
tatin at a dose of 1mg × kg−1 bw, S20 H: hypercholesterolaemic group receiving simvastatin at a dose of 20mg × kg−1 bw, IW H S1: hypercholesterolaemic
group receiving ivabradine and simvastatin at a dose of 1mg × kg−1 bw, IW H S20: hypercholesterolaemic group receiving ivabradine and simvastatin at a
dose of 20mg × kg−1 bw ∗P<0.05 as compared to the control group.
Table 3: Summary statistics (mean ± SD) for blood pressure (mmHg) in normocholesterolaemic rats.
Systolic blood pressure
(mmHg)
Mean blood pressure
(mmHg)
Diastolic blood pressure
(mmHg)
K N 105,57 ± 2,58 93,40 ± 4,55 83,96 ± 2,23
IW N 106,66 ± 2,93 93,47 ± 3,27 85,97 ± 2,25
S1 N 104,53 ± 3,05 93,50 ± 3,13 84,63 ± 2,85
S20 N 106,79 ± 3,44 93,56 ± 5,33 86,92 ± 3,17
IW N S1 105,97 ± 4,37 93,51 ±4,10 85,48 ± 3,35
IW N S20 106,07 ± 5,12 92,95 ± 3,52 84,53 ± 2,82
K N: normocholesterolaemic control group, IW N: normocholesterolaemic group receiving ivabradine, S1 N: normocholesterolaemic group receiving
simvastatin at a dose of 1mg × kg−1 bw, S20 N: normocholesterolaemic group receiving simvastatin at a dose of 20mg × kg−1 bw, IW N S1: normoc-
holesterolaemic group receiving ivabradine and simvastatin at a dose of 1mg × kg−1 bw, IW N S20: normocholesterolaemic group receiving ivabradine and
simvastatin at a dose of 20mg × kg−1 bw.
Table 4: Summary statistics (mean ± SD) for blood pressure (mmHg) in hypercholesterolaemic rats.
Systolic blood pressure
(mmHg)
Mean blood pressure
(mmHg)
Diastolic blood pressure
(mmHg)
K H 107,77 ± 3,80 94,96 ± 3,73 85,86 ± 2,64
IW H 105,46± 2,00 92,63 ± 2,75 86,38 ± 2,19
S1 H 105,47 ± 2,82 93,91 ± 4,14 85,20 ± 3,15
S20 H 106,81 ± 4,01 94,04 ± 3,20 85,32 ± 3,79
IW H S1 105,47 ±3,40 94,48 ± 4,19 86,48 ± 3,42
IW H S20 105,57 ± 3,43 93,95 ± 2,28 86,24 ± 4,33
K H: hypercholesterolaemic control group, IW H: hypercholesterolaemic group receiving ivabradine, S1 H: hypercholesterolaemic group receiving simvas-
tatin at a dose of 1mg × kg−1 bw, S20 H: hypercholesterolaemic group receiving simvastatin at a dose of 20mg × kg−1 bw, IW H S1: hypercholesterolaemic
group receiving ivabradine and simvastatin at a dose of 1mg × kg−1 bw, IW H S20: hypercholesterolaemic group receiving ivabradine and simvastatin at a
dose of 20mg × kg−1 bw.4 The Scientiﬁc World Journal
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Figure 1: PAI–1 blood level (ng/mL) in Wistar rats fed normoc-
holesterolaemic diet. K N: normocholesterolaemic control group,
IW N: normocholesterolaemic group receiving ivabradine, S1 N:
normocholesterolaemic group receiving simvastatin at a dose of
1mg × kg−1 bw, S20 N: normocholesterolaemic group receiving
simvastatin at a dose of 20mg × kg−1 bw, IW N S1: normoc-
holesterolaemic group receiving ivabradine and simvastatin at a
dose of 1mg × kg−1 bw, IW N S20: normocholesterolaemic group
receiving ivabradine and simvastatin at a dose of 20 mg × kg−1 bw,
∗P< 0.05 as compared to the control group, (a) P<0.05 as
compared to rats receiving simvastatin alone, and (b) P<0.05 as
compared to rats receiving ivabradine alone.
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Figure 2: PAI–1 level (ng/mL) in Wistar rats fed hypercholes-
terolaemic diet. K H: hypercholesterolaemic control group, IW H:
hypercholesterolaemic group receiving ivabradine, S1 H: hyperc-
holesterolaemic group receiving simvastatin at a dose of 1mg ×
kg−1 bw, S20 H: hypercholesterolaemic group receiving simvastatin
at a dose of 20mg × kg−1 bw, IW H S1: hypercholesterolaemic
group receiving ivabradine and simvastatin at a dose of 1 mg ×
kg−1 bw, IW H S20: hypercholesterolaemic group receiving ivabra-
dine and simvastatin at a dose of 20mg × kg−1 bw, ∗P<0.05 as
compared to the control group, and (a) P<0.05 as compared to
rats receiving simvastatin alone.
with 1 or 20mg × kg−1 bw simvastatin, a signiﬁcant reduc-
tion of the level of PAI-1 was seen compared to the group
which only received ivabradine (P<0.05) (Figure 1).
In hypercholesterolaemic rats, the levels of PAI-1 in
the control group as well as the group receiving 1mg ×
kg−1 bw simvastatin were comparable. The administration of
ivabradine or 20mg × kg−1 bw simvastatin to hypercholes-
terolaemic rats signiﬁcantly lowered PAI-1 values (P<0.05)
comparedtothecontrolgroup.Concomitantadministration
of ivabradine with 1 or 20mg × kg−1 bw simvastatin, to
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Figure 3: Resting mean heart rate (min−1) in Wistar rats fed nor-
mocholesterolaemic diet. K N: normocholesterolaemic control
group, IW N: normocholesterolaemic group receiving ivabradine,
S1 N: normocholesterolaemic group receiving simvastatin at a
dose of 1 mg × kg−1 bw, S20 N: normocholesterolaemic group
receiving simvastatin at a dose of 20mg × kg−1 bw, IW N S1:
normocholesterolaemic group receiving ivabradine and simvastatin
at a dose of 1 mg × kg−1 bw, IW N S20: normocholesterolaemic
group receiving ivabradine and simvastatin at a dose of 20 mg ×
kg−1 bw, ∗P<0.05 as compared to the control group, (a) P<
0.05 as compared to rats receiving simvastatin alone, (b) P<0.05
as compared to rats receiving ivabradine alone, and (c) P< 0.05 as
compared to rats receiving ivabradine and simvastatin at a dose of
1mg× kg−1 bw.
hypercholesterolaemic rats, did not exacerbate the fall in
PAI-1levelscomparedtothegroupreceivingonlyivabradine
(Figure 2).
4. Discussion
PAI-1(serpin E1) is an inhibitor of t-Pa (tissue plasminogen
activator) and u-Pa (urokinase-type plasminogen activator)
and plays an important role in the regulation of activity
of plasminogen. Raised levels of serum PAI-1 occur in
many pathological conditions and are associated with an
increased risk of cardiovascular complications [18, 19]. In an
earlier study on cell cultures (HMEC and HUVEC), it was
demonstrated that simvastatin signiﬁcantly lowers the level
of PAI-1. The observed eﬀect was dose dependent, and the
mechanism of action most probably involved the pleiotropic
statin pathway [15]. The inﬂuence of simvastatin on PAI-
1 values has been conﬁrmed by clinical trials. It has been
shown that administration of 40mg × kg−1 bw simvastatin
for 8 weeks in patients with metabolic syndrome signiﬁ-
cantly reduced the activity of PAI-1 [14]. The reduction
of PAI-1 expression after “statin” administration has been
evidenced in many preclinical and clinical trials [20–22].
The mechanisms surrounding the inﬂuence of HMG-CoA
on the expression PAI-1 can be diverse. They include an
inﬂuence on the inﬂammatory process, through mitogen-
activated protein (MAP), nuclease factor kappa-B(NF-kB),
phosphatidylinositol 3-kinase (PI3), JNK(c-jun-N-terminal
kinases), and ERK (extracellular signal-regulated kinases), as
well as on the small Rho proteins [23–26]. The inﬂuence ofThe Scientiﬁc World Journal 5
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Figure 4: Resting mean heart rate (min−1) in Wistar rats fed-
hypercholesterolaemic diet. K H: hypercholesterolaemic control
group, IW H: hypercholesterolaemic group receiving ivabradine,
S1 H: hypercholesterolaemic group receiving simvastatin at a
dose of 1 mg × kg−1 bw, S20 H: hypercholesterolaemic group
receiving simvastatin at a dose of 20 mg × kg−1 bw, IW H S1-
hypercholesterolaemic group receiving ivabradine and simvastatin
at a dose of 1 mg × kg−1 bw, IW H S20: hypercholesterolaemic
group receiving ivabradine and simvastatin at a dose of 20 mg ×
kg−1 bw, ∗P<0.05 as compared to control group, (a) P<0.05
as compared to rats receiving simvastatin alone, and (b) P< 0.05
as compared to rats receiving ivabradine alone, (c) P< 0.05 as
compared to rats receiving ivabradine and simvastatin at a dose of
1mg× kg−1 bw.
the small Rho protein family on the regulation of PAI-1 is,
however, very complex and requires further studies [27]. To
the best of our knowledge, this is the ﬁrst study to evaluate
the inﬂuence of ivabradine on PAI-1 values. Ivabradine
may inﬂuence PAI-1 values by means of reducing factors
associated with the inﬂammation process. It has been shown
in E−/− mice that ivabradine modulates the inﬂammation
process by reducing the expression of interleukin–6 (IL-
6) and tumor necrosis factor alpha (TNF-alpha) cytokine
mRNA, which is not observed in wild-type mice [28]. The
beneﬁcial eﬀect of reducing the inﬂammation process might
also be a result of the slowing of the heart rate. In fact,
acceleratingtheheartrateisassociatedwithraisedC-reactive
protein (CRP) [29, 30]. The administration of ivabradine
to animals receiving high dose of simvastatin has no eﬀect
on PAI-1 values compared to the groups receiving only
simvastatin. However, it has been observed that ivabradine
causes the reduction of PAI-1 in animals receiving small
doses of simvastatin.
The mechanism of interaction on heart rate between
simvastatin and ivabradine might involve a metabolic path-
way. Previous pharmacokinetic studies have revealed that
simvastatin might increase ivabradine plasma concentration,
and, in this way, it might inﬂuence the pharmacological
activity of ivabradine [31]. Although simvastatin is reported
to be the substrate for P450 CYP3A4, it was seen to
demonstrate inhibitory activity, as well [32]. The inhibitory
activity of simvastatin is signiﬁcant especially for the lactone
forms rather than its acid forms [33]. Rats do not possess the
CYP3A4isoenzyme,butitsactivitymightbeadoptedbyoth-
ers, for example, CYP 2C11, CYP3A, and CYP2D3 [34, 35].
In our study, a dose-dependent inﬂuence of simvastatin on
heart rate after concomitant administration with ivabradine
was observed. After concomitant administration of a small
dose of simvastatin (1mg × kg−1 bw) with ivabradine,
the heart rates of normo- and hypercholesterolaemic rats
were compared to group receiving ivabradine alone. The
administration of ivabradine with simvastatin given at a
higher dose (20mg × kg−1 bw) caused important drug-
drug interaction and signiﬁcant slowing of the heart rate as
compared to ivabradine alone.
The slowing of heart rate might also be a result of beta-
blockers therapy, however the mechanistic background is
diﬀerent. Only several reports indicate the possible interac-
tion between statins and beta-blockers. Statins reduce the
isoprenoid cholesterol intermediates and as well as dolichols,
geranylgeranoic acid and farnesyl-farnesoic acid and it was
shown that statin inﬂuences the beta-adrenergic stimulation
which is connected with their impact on isoprenylation of G-
protein beta-subunits. [36]. Additionally, it was shown that
simvastatininratsrestoredthesympathetic/parasympathetic
balance [37]. Gentlesk et al. suggested that the impact of
statins on the autonomic nervous system is most probably
the eﬀect of extralipid action of simvastatin [38].
Previous studies being performed in humans [39, 40]
did not reveal apparent antiadrenergic eﬀects of statins such
as a reduction of heart rate, however. Also in our previous
studiessimvastatinadministrationduringtwo[17]andfour -
week (article in press) period did not inﬂuence the heart
rate and blood pressure after metoprolol injection in normo-
and hypercholesterolemic rats, however. In other words, any
signiﬁcant statin intensiﬁcation of heart rate deceleration
after metoprolol administration was not observed.
Another point is if the augmentation of heart rate reduc-
tion by simvastatin might be related to inﬂuence of statin on
vasodilatation with enhancement the endothelium-derived
nitric oxide and elevation the cGMP levels. The impact of
statins on blood pressure and possible statin vasodilatory
properties have been discussed widely [12]. Among sug-
gested pathways leading to possible vasodilatory eﬃcacy of
statins, the restoration of endothelial dysfunction, increased
nitric oxide synthesis with enhancement of eNOS mRNA
stabilization or decreased synthesis of endothelin-1 (ET-
1) are mentioned. The described eﬀects are cholesterol-
independent or “pleiotropic” ones and are the result of, at
least partially, the inhibition of Rho isoprenylation [41, 42].
5. Conclusion
The administration of ivabradine to normocholesterolaemic
and hypercholesterolaemic rats receiving simvastatin signif-
icantly exacerbated the slowing of heart rate with no eﬀect
on blood pressure. The administration of ivabradine has
been shown to demonstrate diﬀerent eﬀects on PAI-1 values
depending on lipid disorders. Concomitant administration
of ivabradine and simvastatin in diﬀerent doses, decrease
PAI-1 blood levels in normo- and hypercholesterolaemic
rats.6 The Scientiﬁc World Journal
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TNF-alpha: Tumor necrosis.
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